Join MySLAS Social

Emerging Microtechnologies and Automated Systems for Rapid Bacterial Identification and Antibiotic Susceptibility Testing

Read this Report

Weian Zhao, Ph.D.
Associate Professor
Sue and Bill Gross Stem Cell Research Center
Chao Family Comprehensive Cancer Center
Edwards Lifesciences Center for Advanced Cardiovascular Technology
Departments of Biomedical Engineering, Biological Chemistry and Pharmaceutical Sciences, University of California, Irvine, CA

Weian Zhao, Ph.D., is an associate professor at University of California, Irvine. His research aims to 1) elucidate and eventually control the fate of transplanted stem cells and immune cells to treat cancer and autoimmune diseases; and 2) develop novel miniaturized devices for early diagnosis and monitoring for conditions including sepsis, antibiotic resistance and cancer. Zhao is also the co-founder of Velox Biosystems Inc, Baylx Inc, and Amberstone Biosciences LLC, start-up companies that aim to develop technologies for rapid diagnosis, stem cell therapy, and drug discovery, respectively. 

Zhao completed his B.Sc. and M.Sc. degrees in chemistry at Shandong University where he studied polymer, surface and colloidal chemistry. He then earned his Ph.D. in chemistry at McMaster University in 2008. During his Ph.D. studies, Zhao focused on the use of functional nucleic acid to structure gold nanoparticles to construct well-defined nanostructures and biosensors.

From 2008 through 2011, Zhao was a Human Frontier Science Program (HFSP) postdoctoral fellow at Harvard Medical School, Brigham and Women’s Hospital and MIT. His research focused on the development of novel molecular, nano- and micro-engineered tools for stem cell therapy and regenerative medicine, diagnosis and in vivo imaging, and elucidating stem cell and cancer biology. 

Zhao has received numerous awards including the MIT Technology Review TR35 Award: The World’s Top 35 Innovators Under the Age of 35 and the NIH Director’s New Innovator Award. 


Listen to his podcast

SLAS publishes two MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

November 27, 2017